Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

After peak in 2020, significant decrease seen in firearm injury-related visit rates year over year from 2020 to 2023 ...

At ObesityWeek 2024, researchers presented the latest data on treatment regimens for chronic weight management, including GLP ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks.

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

The American Academy of Sleep Medicine published guidance regarding the treatment of restless leg syndrome and periodic limb movement disorder.

Ms E performed a comprehensive breast examination and did not find a lump. She did, however, note that the patient’s breasts ...

Respondents who participated in continuing medical education had the highest familiarity with TD therapies. Managing patients with tardive dyskinesia (TD) requires evolving educational needs, with ...

Fatigue, sleep disturbance, executive function, and working memory losses were seen more often in the younger patients (18-44 years) compared with older patients. HealthDay News — Younger and ...